The below scientific publications discuss investigational uses of agents in development and are for informational and educational purposes only. They are not intended to convey conclusions about efficacy or safety. There is no guarantee that sunobinop or tinostamustine will successfully complete development or gain FDA approval.
Sunobinop Scientific Publications
Pharmacology
Manuscripts
| Date | Citation | Link |
|---|---|---|
| August 2025 | In Vitro Pharmacological Evaluation of the Novel NOP Receptor Partial Agonist Sunobinop. Biochem Pharmacol. 2025;238:116972. | Access Publication |
| August 2024 | Evaluation of Sunobinop for Next-Day Residual Effects in Healthy Participants. Front Pharmacol. 2024;15:1432902. | Access Publication |
| March 2024 | Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Ascending Doses of Sunobinop in Healthy Participants. Clin Pharmacol Drug Dev. 2024;13(7):790-800. | Access Publication |
Sleep
Manuscripts
| Date | Citation | Link |
|---|---|---|
| August 2025 | Efficacy and Safety of a Selective Partial Agonist for Nociception/Orphanin-FQ Peptide (NOP) Receptors in Patients with Insomnia Disorder. Br J Clin Pharmacol. Early view online version: 27 August 2025. | Access Publication |
| January 2024 | The Nociceptin/Orphanin FQ Receptor Partial Agonist Sunobinop Promotes Non-REM Sleep in Rodents and Patients with Insomnia. J Clin Invest. 2024;134(1):e171172. | Access Publication |
Abstracts
| Date | Citation | Link |
|---|---|---|
| July 2024 | Results from a Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study of Sunobinop in Subjects Who Are Experiencing Insomnia During Recovery from Alcohol Use Disorder. Drug and Alcohol Dependence. 2024;260(S):110455. | Access Publication |
| May 2020 | Safety, Tolerability, and Efficacy of a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors in Patients with Insomnia Disorder. Sleep. 2020;43(S1):A192. | Access Publication |
| May 2020 | Evaluation of the Human Abuse Potential of Single Oral Doses of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors. Sleep. 2020;43(S1):A191-A192. | Access Publication |
| May 2020 | Activation of Nociceptin/Orphanin-FQ Peptide (NOP) Receptors Produces an Increase in Non-REM Sleep in Rats and Constitutes a Novel and Attractive Target for the Treatment of Insomnia. Sleep. 2020;43(S1):A1. | Access Publication |
Urology
Abstracts
| Date | Citation | Link |
|---|---|---|
| September 2023 | Medical Claims Data Analysis of Comorbidities in Patients with Interstitial Cystitis / Bladder Pain Syndrome. Continence. 2024;7(S1):100823. | Access Publication |
| April 2023 | Effects of Sunobinop (V117957) in a Model of Acute Cystitis Induced by Cyclophosphamide. The Journal of Urology. 2023;209(S4):E152. | Access Publication |
Alcohol Use Disorder (AUD)
Manuscripts
| Date | Citation | Link |
|---|---|---|
| May 2025 | Return to Alcohol Use Among Patients Who are in Recovery from Alcohol Use Disorder with Pharmacologically Treated vs Untreated Insomnia. J Stud Alcohol Drugs. Online 27 May 2025. | Access Publication |
| June 2020 | Current and Potential Pharmacological Treatment Options for Insomnia in Patients with Alcohol Use Disorder in Recovery. Neuropsychopharmacol Rep. 2020;40(3):211-223. | Access Publication |
Abstracts
| Date | Citation | Link |
|---|---|---|
| May 2020 | Psychomotor/Cognitive Effects, Pharmacokinetics and Safety of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors, Administered in Combination with Alcohol in Healthy Subjects. Sleep. 2020;43(S1):A78. | Access Publication |